Cargando…

Molecular Detection of Minimal Residual Disease before Allogeneic Stem Cell Transplantation Predicts a High Incidence of Early Relapse in Adult Patients with NPM1 Positive Acute Myeloid Leukemia

We analyzed the impact of alloHSCT in a single center cohort of 89 newly diagnosed NPM1(mut) AML patients, consecutively treated according to the Northern Italy Leukemia Group protocol 02/06 [NCT00495287]. After two consolidation cycles, the detection of measurable residual disease (MRD) by RQ-PCR w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lussana, Federico, Caprioli, Chiara, Stefanoni, Paola, Pavoni, Chiara, Spinelli, Orietta, Buklijas, Ksenija, Michelato, Anna, Borleri, GianMaria, Algarotti, Alessandra, Micò, Caterina, Grassi, Anna, Intermesoli, Tamara, Rambaldi, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826431/ https://www.ncbi.nlm.nih.gov/pubmed/31569375 http://dx.doi.org/10.3390/cancers11101455

Ejemplares similares

Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1‐JAK2 positive myeloid sarcoma and acute B‐lymphoblastic leukemia
por: Rizzuto, Giuliana, et al.
Publicado: (2022)

High Throughput Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia in the Context of the Prospective Trial 02/06 of the Northern Italy Leukemia Group (NILG)
por: Salmoiraghi, Silvia, et al.
Publicado: (2020)

Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06
por: Caprioli, Chiara, et al.
Publicado: (2020)

P1180: BURKITT INTERNATIONAL PROGNOSTIC INDEX EVALUATED IN PATIENTS TREATED WITH R-GMALL PROTOCOL
por: Rizzuto, Giuliana, et al.
Publicado: (2023)

MRD-Based Therapeutic Decisions in Genetically Defined Subsets of Adolescents and Young Adult Philadelphia-Negative ALL
por: Tosi, Manuela, et al.
Publicado: (2021)

Capture-Based Next-Generation Sequencing Improves the Identification of Immunoglobulin/T-Cell Receptor Clonal Markers and Gene Mutations in Adult Acute Lymphoblastic Leukemia Patients Lacking Molecular Probes
por: Cavagna, Roberta, et al.
Publicado: (2020)

Concurrent Diagnosis of Acute Myeloid Leukemia and Symptomatic COVID-19 Infection: a Case Report Successfully Treated with Azacitidine-Venetoclax Combination
por: Taurino, Daniela, et al.
Publicado: (2021)

Role of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia
por: Lussana, Federico, et al.
Publicado: (2014)

Immature Immunoglobulin Gene Rearrangements Are Recurrent in B Precursor Adult Acute Lymphoblastic Leukemia Carrying TP53 Molecular Alterations
por: Salmoiraghi, Silvia, et al.
Publicado: (2020)

IDH1-R132 changes vary according to NPM1 and other mutations status in AML
por: Falini, Brunangelo, et al.
Publicado: (2019)

Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab
por: Rambaldi, Alessandro, et al.
Publicado: (2020)

Primary Treatment Response Rather than Front Line Stem Cell Transplantation Is Crucial for Long Term Outcome of Peripheral T-Cell Lymphomas
por: Gritti, Giuseppe, et al.
Publicado: (2015)

CD123 Is Consistently Expressed on NPM1-Mutated AML Cells
por: Perriello, Vincenzo Maria, et al.
Publicado: (2021)

Identification of kit(M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response
por: Iurlo, Alessandra, et al.
Publicado: (2014)

Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18–65 years: NILG ALL 10/07
por: Bassan, Renato, et al.
Publicado: (2020)

gDNA qPCR is statistically more reliable than mRNA analysis in detecting leukemic cells to monitor CML
por: Rainero, Alessia, et al.
Publicado: (2018)

Relapse of NPM1-Mutated AML with Extramedullary Manifestation 17 Years after Allogeneic Hematopoietic Stem Cell Transplantation
por: Braune, Jan, et al.
Publicado: (2022)

Is There a Role for Minimal Residual Disease Monitoring in Follicular Lymphoma in the Chemo-Immunotherapy Era?
por: Gritti, Giuseppe, et al.
Publicado: (2017)

Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell–Redirected Bispecific Antibodies
por: Lussana, Federico, et al.
Publicado: (2021)

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
por: Issa, Ghayas C., et al.
Publicado: (2022)

Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML
por: Martelli, Maria Paola, et al.
Publicado: (2021)

Author Correction: High-resolution Nanopore methylome-maps reveal random hyper-methylation at CpG-poor regions as driver of chemoresistance in leukemias
por: Magi, Alberto, et al.
Publicado: (2023)

High-resolution Nanopore methylome-maps reveal random hyper-methylation at CpG-poor regions as driver of chemoresistance in leukemias
por: Magi, Alberto, et al.
Publicado: (2023)

Megakaryoblasts in a newborn with Down syndrome
por: Buoro, Sabrina, et al.
Publicado: (2018)

Mesenchymal Stromal Cells Do Not Increase the Risk of Viral Reactivation Nor the Severity of Viral Events in Recipients of Allogeneic Stem Cell Transplantation
por: Lucchini, Giovanna, et al.
Publicado: (2012)

An intensive approach to treatment for older patients with relapsed isolated NPM1 mutated AML
por: Dukka, Srivasavi, et al.
Publicado: (2015)

Genomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid Leukemia
por: Pagani, Ilaria S., et al.
Publicado: (2014)

Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis
por: McDuff, Fiona Kate Elizabeth, et al.
Publicado: (2011)

RARα2 and PML-RAR similarities in the control of basal and retinoic acid induced myeloid maturation of acute myeloid leukemia cells
por: Gianni, Maurizio, et al.
Publicado: (2016)

Optimal Use of Novel Immunotherapeutics in B-Cell Precursor ALL
por: Lussana, Federico, et al.
Publicado: (2023)

Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1(mut)) for the Treatment of NPM1(mut)-Acute Myeloid Leukemia
por: De Cicco, Marica, et al.
Publicado: (2023)

Switch of the mutation type of the NPM1 gene in acute myeloid leukemia (AML): relapse or secondary AML?
por: Webersinke, G, et al.
Publicado: (2014)

Genetic changes in refractory relapsed acute myeloid leukemia with NPM1 mutation: A case report
por: Wang, Shuang-Ling
Publicado: (2022)

Function of homo- and hetero-oligomers of human nucleoplasmin/nucleophosmin family proteins NPM1, NPM2 and NPM3 during sperm chromatin remodeling
por: Okuwaki, Mitsuru, et al.
Publicado: (2012)

NPM and NPM-MLF1 interact with chromatin remodeling complexes and influence their recruitment to specific genes
por: Darracq, Anaïs, et al.
Publicado: (2019)

Outcomes of Older Patients with NPM1 Mutated and FLT3-ITD Negative Acute Myeloid Leukemia Receiving Allogeneic Transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2020)

Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML
por: Gionfriddo, Ilaria, et al.
Publicado: (2021)

P504: UPDATED DATA FOR ZIFTOMENIB IN PATIENTS WITH NPM1-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
por: Fathi, Amir, et al.
Publicado: (2023)

Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia
por: Kayser, S, et al.
Publicado: (2016)

Bone Marrow Clonogenic Myeloid Progenitors from NPM1-Mutated AML Patients Do Not Harbor the NPM1 Mutation: Implication for the Cell-Of-Origin of NPM1+ AML
por: Diaz de la Guardia, Rafael, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2m906b672al8ae97s3duqabkpq